Sodium Phenylbutyrate
(Synonyms: 苯丁酸钠; 4-PBA sodium; 4-Phenylbutyric acid sodium; Benzenebutyric acid sodium) 目录号 : GC15002
一键复制产品信息
Sodium Phenylbutyrate是一种组蛋白去乙酰化酶（HDAC）抑制剂。
Cas No.:1716-12-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sodium Phenylbutyrate is a histone deacetylase (HDAC) inhibitor. Sodium Phenylbutyrate is metabolized via β-oxidation to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. Sodium Phenylbutyrate exerts antitumor effects by inhibiting PDKs to upregulate PDHC activity and modulating HDAC activity. Sodium Phenylbutyrate can be used in research related to urea cycle disorders and amyotrophic lateral sclerosis[1-4].
In vitro, MGC-803 and BGC-823 gastric cancer cells were treated with Sodium Phenylbutyrate (0.5-10mM) for 16 hours. Sodium Phenylbutyrate induced epithelial-mesenchymal transition (EMT) and promoted cell migration by upregulating IL-8 expression and activating the Gab2-ERK pathway[5]. A scratched IPEC-J2 cell monolayer was treated with Sodium Phenylbutyrate (1.0mM) for 24 hours, which accelerated cell migration and barrier function recovery. When IPEC-J2 cell monolayers were co-treated with DON (2.0μg/mL) or LPS (5.0μg/mL) and Sodium Phenylbutyrate for 48 hours, Sodium Phenylbutyrate accelerated barrier function recovery and upregulated the expression of tight junction proteins ZO-1, occludin, and claudin-1[6].
In vivo, Sprague-Dawley rats exposed to a hypoxic environment at 5500 meters were intraperitoneally administered Sodium Phenylbutyrate (30mg/kg/day) for 10 days. Sodium Phenylbutyrate effectively alleviated hypoxia-induced lipolysis and improved hepatic lipid accumulation, liver injury, and apoptosis[7]. Female Sprague-Dawley rats with protamine/LPS-induced interstitial cystitis were administered Sodium Phenylbutyrate (500mg/kg/day) by gavage for 5 days. Sodium Phenylbutyrate improved bladder micturition function, inhibited endoplasmic reticulum stress, restored autophagic flux, and suppressed bladder oxidative stress, inflammatory reaction, and apoptosis[8].
References:
[1] Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res. 2002 Apr;8(4):1206-12.
[2] Frouco G, Freitas FB, Martins C, et al. Sodium phenylbutyrate abrogates African swine fever virus replication by disrupting the virus-induced hypoacetylation status of histone H3K9/K14. Virus Res. 2017 Oct 15;242:24-29.
[3] Park HJ, Son HJ, Sul OJ, et al. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts. Biochem Pharmacol. 2018 May;151:9-17.
[4] Xiong F, Wang C, Lu J, et al. 4-PBA exerts brain-protective effects against sepsis-associated encephalopathy in a mouse model of sepsis. Exp Neurol. 2024 May;375:114738.
[5] Shi X, Gong L, Liu Y, et al. 4-phenylbutyric acid promotes migration of gastric cancer cells by histone deacetylase inhibition-mediated IL-8 upregulation. Epigenetics. 2020 Jun-Jul;15(6-7):632-645.
[6] Jiang Q, Yin J, Chen J, et al. 4-Phenylbutyric acid accelerates rehabilitation of barrier function in IPEC-J2 cell monolayer model. Anim Nutr. 2021 Dec;7(4):1061-1069.
[7] Xiong Y, Wang Y, Xiong Y, et al. 4-PBA inhibits hypoxia-induced lipolysis in rat adipose tissue and lipid accumulation in the liver through regulating ER stress. Food Sci Nutr. 2023 Feb 9;11(3):1223-1231.
[8] Jia L, Jingzhen Z, Xinliang Y, et al. 4-PBA inhibits endoplasmic reticulum stress to improve autophagic flux in the treatment of protamine/lipopolysaccharide-induced interstitial cystitis in rats. Sci Rep. 2023 Aug 28;13(1):14057.
Sodium Phenylbutyrate是一种组蛋白去乙酰化酶（HDAC）抑制剂。Sodium Phenylbutyrate通过β-氧化代谢为乙酸苯酯并与谷氨酰胺结合生成苯乙酰谷氨酰胺。Sodium Phenylbutyrate通过抑制PDKs上调PDHC活性及调控HDACs活性发挥抗肿瘤作用。Sodium Phenylbutyrate可用于尿素循环障碍和肌萎缩侧索硬化症的相关研究[1-4]。
在体外，Sodium Phenylbutyrate（0.5-10mM）处理MGC-803和BGC-823胃癌细胞16小时。Sodium Phenylbutyrate可诱导上皮-间质转化（EMT）并促进细胞迁移，通过上调IL-8表达并激活Gab2-ERK通路[5]。Sodium Phenylbutyrate（1.0mM）处理划伤的IPEC-J2细胞单层24小时，加速了细胞迁移和屏障功能恢复；与DON（2.0μg/mL）或LPS（5.0μg/mL）同时处理IPEC-J2细胞单层48小时。Sodium Phenylbutyrate加速了屏障功能的恢复，并上调了紧密连接蛋白ZO-1、occludin和claudin-1的表达[6]。
在体内，Sodium Phenylbutyrate（30mg/kg/day）腹腔注射处理暴露于5500米缺氧环境的Sprague-Dawley大鼠10天。Sodium Phenylbutyrate有效减轻了缺氧诱导的脂肪分解，同时改善了肝脏脂质积累、肝损伤和细胞凋亡[7]。Sodium Phenylbutyrate（500mg/kg/day）灌胃处理鱼精蛋白/LPS诱导的间质性膀胱炎雌性Sprague-Dawley大鼠5天。Sodium Phenylbutyrate改善了膀胱排尿功能，抑制了内质网应激，恢复了自噬流，并抑制了膀胱氧化应激、炎症反应和细胞凋亡[8]。
| Cell experiment [1]: | |
Cell lines | MGC-803 and BGC-823 gastric cancer cells |
Preparation Method | MGC-803 and BGC-823 cells were treated with Sodium Phenylbutyrate at concentrations of 0, 0.5, 1, 2, 5, and 10mM for 16 hours. |
Reaction Conditions | 0.5-10mM; 16h |
Applications | Sodium Phenylbutyrate induced epithelial-mesenchymal transition (EMT) and promoted cell migration in gastric cancer cells. Sodium Phenylbutyrate upregulated IL-8 expression and activated the downstream Gab2-ERK pathway. |
| Animal experiment [2]: | |
Animal models | Female Sprague-Dawley rats |
Preparation Method | Rats were randomized into three groups: sham controls (N), interstitial cystitis (IC) alone, and IC+ Sodium Phenylbutyrate. The IC model was established by intravesical perfusion with protamine (10mg/ml) for 30min followed by LPS (2mg/ml) for 45min. The IC+ Sodium Phenylbutyrate group received Sodium Phenylbutyrate treatment by gavage once daily for 5 consecutive days starting from model establishment. |
Dosage form | 500mg/kg/day; by gavage; 5 days |
Applications | Sodium Phenylbutyrate treatment significantly improved bladder micturition function, inhibited endoplasmic reticulum stress (ERS), recovered autophagic flux, and suppressed bladder oxidative stress, inflammatory reaction and apoptosis in protamine/lipopolysaccharide-induced interstitial cystitis rats. |
References: | |
| Cas No. | 1716-12-7 | SDF | |
| 别名 | 苯丁酸钠; 4-PBA sodium; 4-Phenylbutyric acid sodium; Benzenebutyric acid sodium | ||
| 化学名 | sodium;4-phenylbutanoate | ||
| Canonical SMILES | C1=CC=C(C=C1)CCCC(=O)[O-].[Na+] | ||
| 分子式 | C10H11O2.Na | 分子量 | 186.18 |
| 溶解度 | ≥ 27.65 mg/mL in Water, ≥ 6.3 mg/mL in DMSO, ≥ 50.9 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.3711 mL | 26.8557 mL | 53.7115 mL |
| 5 mM | 1.0742 mL | 5.3711 mL | 10.7423 mL |
| 10 mM | 537.1 μL | 2.6856 mL | 5.3711 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet